Inhibitory effect of endostatin combined with paclitaxel‑cisplatin on breast cancer in xenograft-bearing mice

Sun,Jianguo; Deng,Li; Duan,Yuzhong; Chen,Fanglin; Wang,Xinxin; Li,Dezhi; Chen,Zhengtang

doi:10.3892/etm.2011.384

February 2012 Volume 3 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2012 Volume 3 Issue 2

Full Size Image

Article Open Access

Inhibitory effect of endostatin combined with paclitaxel‑cisplatin on breast cancer in xenograft-bearing mice

Authors:
- Jianguo Sun
- Li Deng
- Yuzhong Duan
- Fanglin Chen
- Xinxin Wang
- Dezhi Li
- Zhengtang Chen
View Affiliations / Copyright

Affiliations: Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China, Maternal and Child Health Hospital of Chongqing City, Chongqing 400010, P.R. China
Pages: 159-164
|
Published online on: November 18, 2011

https://doi.org/10.3892/etm.2011.384
Expand metrics +

Abstract

In the present study, we aimed to investigate the tumor-inhibiting effects of recombinant human endostatin (rhES) combined with paclitaxel-cisplatin (TP regimen) on human breast cancer in xenograft-bearing nude mice. A total of 24 mice bearing human breast cancer xenografts were administered both rhES and TP, TP alone, rhES alone or saline. The tumor growth inhibition was observed. Serum vascular endothelial growth factor (VEGF) levels and microvessel density (MVD) were determined by ELISA and immunohistochemistry, respectively. Cell apoptosis was detected using terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) staining. Survival time was observed in another 24 nude mice with the same treatment. MVD expression in the group administered rhES and TP was lower than that in the other groups (P<0.05); serum VEGF levels in the combined drug group were lower compared to the other groups; the apoptotic index increased in the combined drug group. We conclude that the effect of the TP regimen combined with rhES on breast cancer is better than that of the TP regimen alone.

View Figures

View References

1.	J FolkmanWhat is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst8246199010.1093/jnci/82.1.41688381
2.	MS O’ReillyT BoehmY ShingEndostatin: an endogenous inhibitor of angiogenesis and tumor growthCell882772851997
3.	YM KimS HwangBJ PyunEndostatin blocks VEGF-mediated signalling via direct interaction with KDR/Flk-1J Biol Chem2772787227879200210.1074/jbc.M20277120012029087
4.	J HanaiM DhanabalSA KarumanchiEndostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1J Biol Chem2771646416469200210.1074/jbc.M11227420011815623
5.	NJ MacDonaldWY ShiversDL NarumEndostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatinJ Biol Chem2762519025196200110.1074/jbc.M10074320011335715
6.	SP BalasubramanianSS CrossJ GlobeEndostatin gene variation and protein levels in breast cancer susceptibility and severityBMC Cancer7107114200710.1186/1471-2407-7-10717587451
7.	JW WangY SunYY LiuResults of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patientsZhongguo Fei Ai Za Zhi8283290200521108883
8.	L YangJW WangY SunRandomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancerZhonghua Zhong Liu Za Zhi28138141200616750022
9.	SH TehAD HillAW LeeRaised plasma endostatin levels correlate inversely with breast cancer angiogenesisJ Surg Res116165171200410.1016/S0022-4804(03)00282-814732364
10.	J ZhaoF YanH JuCorrelation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancerCancer Lett2048795200410.1016/j.canlet.2003.09.01814744538
11.	K LibyB NeltnerL MohametEndostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growthCancer Biol Ther24852200310.4161/cbt.17912673115
12.	QR ChenD KumarSA StassLiposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude miceCancer Res59330833121999
13.	JG SunY WangZT ChenDetection of lymphangiogenesis in non-small cell lung cancer and its prognostic valueJ Exp Clin Cancer Res282127200910.1186/1756-9966-28-2119216806
14.	B UzzanP NicolasM CucheratMicrovessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysisCancer Res6429412955200410.1158/0008-5472.CAN-03-195715126324
15.	K ByrnesS WhiteQ ChuHigh eIF4E, VEGF and micro-vessel density in stage I to III breast cancerAnn Surg243684690200610.1097/01.sla.0000216770.23642.d816633004
16.	T BachelotD RatelC Menetrier-CauxAutoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcomeBr J Cancer9410661070200610.1038/sj.bjc.660303716552441
17.	LJ JiaHM XuDY MaEnhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma modelCancer Biol Ther4840845200510.4161/cbt.4.8.189116210914
18.	X LuoJM SlaterDS GridleyEnhancement of radiation effects by pXLG-mEndo in a lung carcinoma modelInt J Radiat Oncol Biol Phys63553564200510.1016/j.ijrobp.2005.01.03815964154
19.	M SchmidtG SchlerP GruensfelderDifferential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell lineEur Arch Otorhinolaryngol263127134200610.1007/s00405-005-0936-z16380805
20.	GZ ZhaoXD QiZK ChangInhibitory effect of recombinant human endostatin combined with rAd/p53 on graft model of human breast cancer in nude miceChin J Cancer Res178438462007

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Inhibitory effect of endostatin combined with paclitaxel‑cisplatin on breast cancer in xenograft-bearing mice

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles